亚虹医药在ECC发布APL-1401Ⅰb期临床试验相关数据

Core Viewpoint - APL-1401, an innovative oral drug developed by the company for the treatment of moderate to severe active ulcerative colitis, has had its phase Ib clinical trial results selected for presentation at the 19th European Colorectal Congress (ECC) [1] Group 1: Clinical Trial Results - The phase Ib clinical trial results of APL-1401 were presented in poster format at the ECC [1] - APL-1401 is designed to treat autoimmune diseases through a novel mechanism of action [1] Group 2: Drug Mechanism - APL-1401 is a potent and selective dopamine β-hydroxylase (DBH) inhibitor [1] - By inhibiting DBH, APL-1401 blocks the only catalytic enzyme for the synthesis of norepinephrine (NE) from dopamine (DA), leading to increased DA and decreased NE, which helps restore intestinal immune homeostasis [1]